DGAP-News: First subject dosed in Lipigon's phase I clinical study with antisense oligonucleotide candidate derived from Secarna Pharmaceutical's LNAplus™ technology platform
DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Study First subject dosed in Lipigon’s phase I clinical study with antisense oligonucleotide candidate derived from Secarna Pharmaceutical’s LNAplus™ technology platform 31.05.2022 / 14:00 The issuer is solely responsible for th...
Anne Hennecke Brittney Sojeva Alexander Gebauer Planegg Martinsried Secarna Lnaplus Lipigon Pharmaceuticals Ab Secarna Pharmaceuticals Gmbh Co
Source: boersennews.de